They have at least one thing in common: An exciting pipeline.

EU health ministers split over a proposal to give certain innovative medicines an extra year of market protection, with EU ...

Veraxa Biotech (VRXA) rated Sell: shares look overvalued post‑SPAC. The pipeline’s fragility is pronounced. See here for more ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

It's important to consider your comfort with risk before diving in.

Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

As the technology transforms scientific discovery, industry players are also grappling with the extent of its real-world use ...

While SpaceX dazzles with a $2 trillion valuation, Massachusetts’ biotech sector is quietly stacking wins that save lives and ...

Ernst & Young's 2026 biotech report shows 13% revenue growth to $232B, but US policy shifts, patent cliffs and uneven ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...